An interventional study of Active Transcranial Temporal Interference (TI) Stimulation and Sham Transcranial Temporal Interference (TI) Stimulation in Major Depressive Disorder (MDD and Temporal Interference (TI) Electrical Stimulation, sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center — 12 open to participants now, 12 under way, none of them phase 3. Depressive Disorder, Major · Shanghai Mental Health Center.
Among the 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center, this one is the 27th largest by planned enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2026, is one of 17 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 36th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →12 of the 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:
Shanghai Mental Health Center · Sites in China
Ages 18–65
Shanghai Mental Health Center · Sites in China
Ages 16–65
Shanghai Mental Health Center · Sites in China
Ages 18+
Shanghai Mental Health Center · Sites in China
Ages 12+ · Healthy volunteers
Shanghai Mental Health Center · Sites in China
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 2 · Phase 4 6
First in 2009; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 74 is close to the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 180 across the 32 interventional studies, 370 across the 8 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 96 are open to participants now.
3 of the studies in Depressive Disorder, Major by Shanghai Mental Health Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06409325Shanghai Mental Health CenterEffectiveness of MST Versus ECT for Major Depressive Episode | 2026-12-30 |
| NCT06417437Shanghai Mental Health CenterNon-invasive BCI and Application Verification for Depressed People | 2027-07-31 |
| NCT07941687Shanghai Mental Health CenterEfficacy and Mechanisms of Time-Domain Interferential Transcranial Electrical Stimulation in Treating Depression Associated With Childhood Trauma | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Efficacy and Mechanisms of Time-Domain Interferential Transcranial Electrical Stimulation in Treating Depression Associated with Childhood Trauma Major depressive disorder (MDD) is a prevalent mental illness characterized by high suicide rates and substantial social burden. According to the World Health Organization's (WHO) Global Health Assessment Report on Depression, the global prevalence of MDD reached 350 million cases in 2021, making it the second leading cause of death among individuals aged 15-29 years. MDD is defined by core symptoms of persistent low mood and anhedonia, often accompanied by cognitive, behavioral, and physiological disturbances. These symptoms significantly impair individuals' daily functioning, social interactions, and occupational performance, and some patients may even engage in self-harm or suicidal behaviors[1,2]. MDD imposes a heavy burden on global disease burden, as well as on affected individuals, their families, and society at large.
Existing studies have identified childhood trauma as a major risk factor for MDD. Epidemiological research indicates that individuals who experience childhood trauma face a higher risk of developing MDD, anxiety disorders, or comorbid conditions. Childhood trauma may account for 28.9% of all mental disorders, exerting a lifelong impact on physical and mental health. Notably, 45.59% of MDD patients have a history of at least one type of childhood trauma. Adults with a history of childhood trauma are 2.66-3.73 times more likely to develop MDD compared to those without such experiences.
Animal studies suggest that environmental stress can induce depression-like behaviors in adolescent female rats, accompanied by elevated levels of corticosterone (CORT) and cholecystokinin (CCK), as well as reduced neuropeptide Y (NPY) expression[3,4,5,6]. However, there are currently no effective and safe pharmacological treatments for childhood trauma in clinical practice, and the overall quality of existing evidence remains low. While psychological interventions have been shown to reduce depressive symptoms in MDD patients with childhood trauma, the supporting evidence from evidence-based medicine is insufficient. Therefore, effective, non-pharmacological, well-tolerated, and accessible treatment modalities are crucial for managing MDD complicated by childhood trauma. Research has explored the underlying physiological mechanisms of childhood trauma from perspectives including neuroendocrinology, neuroinflammation, and neuroimaging, but a clear and comprehensive explanation remains elusive.
Temporal interference (TI) electrical stimulation is an emerging non-invasive brain stimulation technique. It utilizes two high-frequency carrier waves to generate low-frequency envelope oscillations in deep brain regions, enabling precise targeted modulation of subcortical structures such as the basal ganglia. Preliminary studies have demonstrated the potential clinical efficacy of TI in treating depression and trauma-related disorders. This paper reviews the research progress and future prospects of TI electrical stimulation in the management of MDD with childhood trauma.
Experimental Rationale 2.1 Preclinical Animal Studies and Literature Basis 2.1.1 Association Between Childhood Trauma and Major Depressive Disorder Extensive epidemiological and clinical research has confirmed that childhood trauma is a critical risk factor for MDD. Approximately 45.59% of MDD patients have a history of at least one type of childhood trauma, with a 2.66-3.73-fold increased risk of developing MDD compared to trauma-free individuals. Childhood trauma is closely linked to structural and functional abnormalities in brain regions such as the hippocampus, amygdala, and prefrontal cortex, as well as hypothalamic-pituitary-adrenal (HPA) axis dysfunction and systemic inflammatory responses (e.g., elevated IL-6 and TNF-α levels).
2.1.2 Neuromodulatory Potential of Transcranial Temporal Interference Stimulation (TI) First proposed by Grossman et al. in 2017, TI is a non-invasive deep brain stimulation technique. Preclinical studies in mice have demonstrated that TI can precisely modulate neural activity in deep brain regions such as the hippocampus, inducing c-fos expression and behavioral changes. Subsequent research in rhesus monkeys and human models has further validated the safety of TI and its ability to effectively regulate deep brain structures (e.g., amygdala, nucleus accumbens, prefrontal cortex), with promising results in improving depressive and anxiety symptoms, as well as cognitive function.
2.1.3 Mechanisms of Action of TI TI generates low-frequency envelope electric fields in deep brain regions through the interference of two high-frequency currents. It primarily modulates neuronal activity via subthreshold stimulation rather than directly evoking action potentials. Studies in non-human primates and humans have confirmed that TI can regulate neural oscillations, improve mood and cognitive function, and is associated with mild adverse effects (e.g., fatigue, headache), demonstrating good safety and feasibility for double-blind trials.
2.2 Participant Selection Rationale 2.2.1 Study Population The study population consists of patients with major depressive disorder (MDD) and a history of childhood trauma. Given the high prevalence of childhood trauma in MDD and its impact on treatment response, this study specifically focuses on this subgroup to explore their unique neural circuitry and immune mechanisms.
2.2.2 Inclusion Criteria Aged 18-65 years; Meets the ICD-11 diagnostic criteria for depressive episode; Scores ≥17 on the 17-item Hamilton Depression Rating Scale (HAMD-17); Stratified by scores on the Childhood Trauma Questionnaire-Short Form (CTQ-SF) to ensure inter-group comparability and targeted mechanistic exploration.
2.2.3 Exclusion Criteria Patients with severe physical illnesses, substance abuse disorders, bipolar disorder, or a history of other mental illnesses are excluded to control for confounding factors and ensure the internal validity of the study results.
2.3 Dosage Selection/Intervention Protocol Rationale 2.3.1 TI Intervention Parameters Based on previous preclinical and clinical studies, TI employs individualized electrode placement optimized using structural MRI data from each participant to maximize electric field distribution in target regions. The intervention consists of 3 daily sessions, each lasting 30 minutes with 30-minute intervals between sessions, for 14 consecutive days. This protocol has demonstrated good tolerability and neuromodulatory efficacy in prior research, with current intensity controlled within a safe range (\<2mA) to avoid tissue damage or significant discomfort.
2.3.2 Concomitant Medication All patients receive a standardized dose of escitalopram oxalate (10 mg/day) as a basic treatment to control for confounding effects of medication and highlight the adjunctive therapeutic efficacy and mechanistic role of TI.
2.4 Endpoint Selection Rationale 2.4.1 Primary Efficacy Endpoint The primary efficacy endpoint is the reduction rate of HAMD-17 scores from baseline to the end of the 2-week treatment period. The HAMD-17 is an internationally recognized tool for assessing depressive symptoms with excellent reliability, validity, and clinical relevance.
2.4.2 Secondary Endpoints Neuroimaging Indicators: Resting-state functional magnetic resonance imaging (rs-fMRI) is used to evaluate changes in functional connectivity within the thalamocortical circuit, revealing the circuit remodeling effects of TI.
Immunological Indicators: Serum levels of inflammatory cytokines including IL-2, IL-6, IL-10, IL-17A, IL-22, and TNF-α are measured to explore the central-peripheral immune regulatory pathway.
Cognitive and Emotional Scales: The Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) are used to supplement the assessment of emotional and cognitive improvements.
2.5 Risk and Benefit Rationale 2.5.1 Risk Control TI is a non-invasive stimulation technique, and previous clinical studies have reported mild and transient adverse effects (e.g., fatigue, scalp tingling). This study will strictly adhere to safety protocols, monitor participants' responses in real-time, and establish criteria for participant withdrawal and trial termination to ensure the rights and safety of all subjects.
2.5.2 Benefit Analysis For Participants: Free professional assessments and access to a novel non-pharmacological treatment option, with potential for symptom relief and functional improvement.
For Science and Society: Elucidating the mechanisms of TI in trauma-related depression to advance the development of individualized neuromodulatory therapies, with significant clinical and scientific value.
Research Objectives This study aims to prospectively recruit MDD patients with or without childhood trauma to conduct a mechanistic investigation. Through multimodal integrative analysis of central rs-fMRI data and peripheral fluid biomarkers, the study will systematically elucidate the mechanisms underlying the antidepressant effects of transcranial temporal interference stimulation via modulation of the thalamocortical circuit.
Research Overview 4.1 Study Design 4.1.1 Overall Design 4.1.1.1 Research Hypotheses
The study proposes the following core hypotheses:
Primary Hypothesis: Transcranial temporal interference stimulation (TI) combined with escitalopram oxalate will result in a significantly greater reduction in depressive symptoms (defined as a ≥50% reduction in HAMD-17 scores) compared to medication alone in MDD patients with childhood trauma.
Mechanistic Hypothesis: TI exerts antidepressant effects by modulating functional connectivity in the thalamocortical circuit and regulating peripheral inflammatory cytokine levels (e.g., IL-6, TNF-α), thereby forming a bidirectional central-peripheral regulatory pathway.
4.1.1.2 Study Design Type This study adopts a randomized, double-blind, sham-controlled, parallel-group design.
4.1.1.3 Randomization Method Block randomization will be used to generate a random sequence via computer algorithms, ensuring balanced sample sizes between groups. The random sequence will be generated and stored by an independent researcher not involved in participant recruitment or assessment. After signing the informed consent form and completing baseline evaluations, participants will be assigned to respective groups by researchers based on random numbers.
4.1.1.4 Blinding Design A double-blind design will be implemented in this study. 4.1.1.5 Study Center Setting This is a single-center study, with all participants recruited from the outpatient and inpatient departments of Shanghai Mental Health Center.
4.1.2 Study Procedures and Methods 4.1.2.1 Study Type This project is a prospective, randomized, double-blind, sham-controlled, single-center clinical mechanistic study.
4.1.2.2 Study Duration Total study duration: Approximately 12 months (including participant recruitment, intervention, follow-up, and data analysis).
Individual participant duration: 4 weeks (including 2 weeks of intervention and 2 weeks of follow-up).
4.1.2.3 Primary Outcome Measures and Assessment Methods Efficacy Indicators Primary Efficacy Indicator: Scores and reduction rates on the 17-item Hamilton Depression Rating Scale (HAMD-17).
Secondary Efficacy Indicators: Scores on the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI).
Mechanistic Indicators Neuroimaging Indicators: Resting-state functional magnetic resonance imaging (rs-fMRI) to assess functional connectivity of the thalamocortical circuit; high-resolution 3D T1-weighted imaging (3D T1WI) for structural brain analysis; diffusion tensor imaging (DTI) for white matter tract analysis.
Immunological Biomarkers: Serum levels of inflammatory cytokines including IL-2, IL-6, IL-10, IL-17A, IL-22, and TNF-α, measured using enzyme-linked immunosorbent assay (ELISA).
Safety Indicators: All adverse events (e.g., headache, fatigue, scalp discomfort) will be recorded through clinical observation and spontaneous reporting by participants.
4.1.2.4 Study Procedures and Phase Arrangements Phase 1: Screening and Baseline Period (Day -7 to Day 0) Study Content and Procedures ① Recruitment and Informed Consent: Potential participants are recruited from the outpatient and inpatient departments of Shanghai Mental Health Center. Researchers provide a detailed explanation of the study content, potential risks, and benefits, and participants sign a written informed consent form.
Confirmation of diagnosis by psychiatrists according to ICD-11 criteria; Administration of standardized scales including the Childhood Trauma Questionnaire-Short Form (CTQ-SF), HAMD-17, 14-item Hamilton Anxiety Rating Scale (HAMA-14), BAI, BDI, and Connor-Davidson Resilience Scale (CD-RISC); Collection of demographic data (age, gender, education level, marital status, etc.) and clinical data (number of depressive episodes, medication history, etc.).
③ Baseline Examinations: Multimodal MRI scans (3D T1WI, DTI, rs-fMRI); Collection of 5-10 mL of peripheral venous blood for baseline measurement of inflammatory cytokine levels (IL-2, IL-6, IL-10, IL-17A, IL-22, TNF-α).
Collected Samples and Data ① Data: Signed informed consent forms, demographic and clinical data questionnaires, baseline scale scores.
② Samples: Baseline blood samples. Collection Methods: Face-to-face interviews, paper/electronic questionnaires, venous blood collection, MRI scanning.
Phase 2: Intervention Period (Day 1 to Day 14) Study Content and Procedures ① Randomization: Eligible participants are randomly assigned in a 1:1 ratio to either the "TI active stimulation + medication group" or the "TI sham stimulation + medication group".
② Intervention Measures: All participants receive oral escitalopram oxalate 10 mg once daily in the morning.
TI stimulation: Physicians perform transcranial temporal interference stimulation using individualized head models for each participant. The intervention consists of 3 daily sessions (30 minutes per session, with 30-minute intervals between sessions) for 14 consecutive days.
③ Mid-term Assessment (around Day 7, optional): Brief evaluations using the HAMD-17, BAI, and BDI may be conducted to monitor symptom changes based on protocol flexibility.
Collected Samples and Data
① Data: Medication adherence records, TI stimulation treatment logs, adverse event records, mid-term scale scores (if applicable).
Follow-up Method: Outpatient visits. Participants are required to attend the hospital daily for TI stimulation and medication management.
Phase 3: Post-intervention Assessment (Day 14 ± 2 days) Study Content and Procedures
① Efficacy and Safety Assessments: Re-administration of the HAMD-17, HAMA-14, BAI, and BDI scales.
② Reassessment of Mechanistic Indicators: Second round of multimodal MRI scans; Collection of a second peripheral venous blood sample for post-intervention measurement of inflammatory cytokine levels.
③ Safety Assessment: Systematic recording of all adverse events occurring during the intervention period.
Collected Samples and Data
① Data: Post-intervention scale scores, adverse event records.
② Samples: Post-intervention blood samples. Collection Methods: Face-to-face interviews, venous blood collection, MRI scanning.
Follow-up Method: Outpatient visits. Phase 4: Follow-up Period (Day 42 ± 3 days, i.e., 4 weeks after intervention completion) Study Content and Procedures
Efficacy and Safety Follow-up: Conducted via outpatient visits or telephone interviews.
Scale Assessments: Administration of the HAMD-17, BAI, and BDI scales. ③ Adverse Event and Concomitant Medication Inquiry: Recording of any adverse events and concomitant medications since the last visit.
Collected Samples and Data
① Data: Follow-up scale scores, records of adverse events and concomitant medications.
② Samples: Follow-up blood samples (if follow-up is conducted via telephone, participants will be required to visit the hospital separately for blood collection).
Follow-up Method: Outpatient visits are preferred; some assessments may be conducted via telephone if necessary, but blood sample collection must be completed during outpatient visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Active Transcranial Temporal Interference (TI) Stimulation · Drug: Escitalopram Oxalate Medication
Device: Sham Transcranial Temporal Interference (TI) Stimulation · Drug: Escitalopram Oxalate Medication
Active transcranial temporal interference (TI) stimulation is administered using individualized electrode placement based on structural MRI. Participants receive 3 sessions per day, each lasting 30 minutes, with 30-minute intervals between sessions, for 14 consecutive days.
Sham transcranial temporal interference (TI) stimulation mimics the setup and schedule of active stimulation but does not deliver effective therapeutic stimulation. Participants receive 3 sessions per day, each lasting 30 minutes, with 30-minute intervals between sessions, for 14 consecutive days.
Participants receive escitalopram oxalate at a dose of 10 mg once daily for 14 consecutive days.
Change in depression severity measured by the Hamilton Depression Rating Scale (HAMD-17)
Change in HAMD-17 total score from baseline to Week 2.
Time frame: Baseline to Week 2
Change in serum inflammatory cytokine levels
Changes in serum levels of IL-2, IL-6, IL-10, IL-17A, IL-22, and TNF-α from baseline to Week 2 will be assessed to evaluate the inflammatory response.
Time frame: Baseline to Week 2
Change in functional connectivity measured by resting-state fMRI
Changes in resting-state functional connectivity will be assessed from baseline to Week 2 using rs-fMRI to evaluate neural network alterations associated with the intervention.
Time frame: Baseline to Week 2
Change in depressive symptoms measured by the Beck Depression Inventory (BDI)
Changes in depressive symptom severity will be assessed using the Beck Depression Inventory (BDI) from baseline to Week 2.
Time frame: Baseline to Week 2
Change in anxiety symptoms measured by the Beck Anxiety Inventory (BAI)
Changes in anxiety symptom severity will be assessed using the Beck Anxiety Inventory (BAI) from baseline to Week 2.
Time frame: Baseline to Week 2
Response rate based on HAMD-17
Proportion of participants achieving a ≥50% reduction in HAMD-17 total score from baseline to Week 2.
Time frame: Baseline to Week 2
PDFs hosted by the registry, ClinicalTrials.gov.
Start is estimated for Dec 2026; primary completion for Nov 2027, 10 months later.
Of 651 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 10 months is below that.
Counting every sponsor, half of 691 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Mental Health Center →